Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are in generally good physical condition, able to carry out normal daily activities with little or no limitation (rated 0 or 1 on a standard medical scale called ECOG)
• People who have been confirmed through a tissue or cell sample to have stage IV non-small cell lung cancer (an advanced form of lung cancer)
• People whose cancer has a specific type of gene change (mutation) in the EGFR gene, specifically the L858R or 19del type
• People whose cancer has stopped responding to first-line treatment with a third-generation EGFR-targeted therapy drug
• People who have at least one tumour that can be measured on a scan
• People who have cancer that has spread to the brain may be considered, but only if they have no brain-related symptoms and the brain lesions are stable and do not require steroid treatment
• Men and women of reproductive age who agree to use contraception during the trial (such as surgical sterilisation, the pill, an intrauterine device, or condoms)
• People with a life expectancy of at least 3 months
• People whose blood test results in the week before joining show that bone marrow, liver, and kidney function all meet the specific levels required by the trial (confirm with trial site for exact values)
• People who are able to understand the study and sign a consent form voluntarily

Who may not be able to join:

• People who have serious autoimmune diseases, such as active inflammatory bowel disease (Crohn's disease or ulcerative colitis), rheumatoid arthritis, scleroderma, lupus, or autoimmune blood vessel inflammation
• People who have symptomatic interstitial lung disease, or active lung inflammation (whether caused by infection or not)
• People who have risk factors for a hole forming in the bowel (intestinal perforation), such as active diverticulitis, an abscess in the abdomen, a bowel blockage, abdominal cancer, or other known risk factors
• People who have a history of another type of cancer
• People who have active infections, heart failure, a heart attack in the past 6 months, unstable chest pain (angina), or unstable irregular heartbeat
• People whose physical examination or lab results suggest the trial could interfere with results or increase the risk of complications, as judged by the treating doctor, or who have other conditions that cannot be controlled
• People who the treating doctor believes currently need radiation therapy to relieve symptoms
• People whose cancer contains a mix of small cell lung cancer
• People who are pregnant or breastfeeding
• People who have a condition that weakens the immune system from birth or due to illness, including HIV, or who have had an organ transplant or stem cell transplant
• People with known active hepatitis B, hepatitis C, or active tuberculosis
• People who have received a cancer vaccine or any non-influenza vaccine within 4 weeks before starting treatment (note: standard inactivated flu vaccines are generally allowed, but live nasal spray flu vaccines are not)
• People who are currently using other immunotherapy, chemotherapy, drugs from another clinical trial, or who need long-term steroid treatment
• People who have psychiatric disorders, substance use issues, or other social circumstances that a doctor determines would affect their ability to follow the trial requirements
• People who are allergic to or medically unable to receive PD-1 antibody drugs, VEGF antibody drugs, or chemotherapy drugs used in this trial

Important: Always verify eligibility with the trial site directly before applying.